Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
The USFDA has issued 5 observations pursuant to the completion of audit
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
_256_384.png)
Breakthrough Therapy designation for pain associated with DPN granted by FDA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated
